Ariane Mallat, Sophie Lotersztajn  Journal of Hepatology 

Slides:



Advertisements
Similar presentations
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Advertisements

Omega 3 – Omega 6: What is right for the liver? Ashraf Mohammad El-Badry, Rolf Graf, Pierre-Alain Clavien Journal of Hepatology Volume 47, Issue 5, Pages.
Don C. Rockey  Clinical Gastroenterology and Hepatology 
Volume 63, Issue 1, Pages (July 2015)
Vincent Leroy, Jean-Pierre Zarski  Journal of Hepatology 
Volume 46, Issue 3, Pages (March 2007)
Inflammasomes in liver diseases
Volume 50, Issue 4, Pages (April 2009)
Tiny RNA with great effects: miR-155 in alcoholic liver disease
Hepatic CD141+IFNλ+ DC subset: One against all?
The yin and yang of evasion and immune activation in HCC
Reactive oxygen species in the normal and acutely injured liver
Cédric Coulouarn, Bruno Clément  Journal of Hepatology 
Matthew T. Kitson, Stuart K. Roberts  Journal of Hepatology 
Volume 57, Issue 1, Pages 6-8 (July 2012)
Don C. Rockey  Clinical Gastroenterology and Hepatology 
NS5A inhibitors in the treatment of hepatitis C
Hedgehog signaling in the liver
The function of serotonin within the liver
Immigration and viral hepatitis
Daniel A. Langer, Vijay H. Shah  Journal of Hepatology 
Figure 1 Functions, features and phenotypes of HSCs in normal and diseased livers Figure 1 | Functions, features and phenotypes of HSCs in normal and diseased.
Living donor liver transplantation: is the hype over?
Senescence: Not Just for Tumor Suppression
Nicolas Moniaux, Jamila Faivre  Journal of Hepatology 
Mechanisms of Hepatic Fibrogenesis
Mesenchymal stromal cell therapy for liver diseases
Volume 59, Issue 3, Pages (September 2013)
Marina Berenguer, Detlef Schuppan  Journal of Hepatology 
Inflammation and portal hypertension – The undiscovered country
From immunosuppression to tolerance
Hepatitis C core protein – The “core” of immune deception?
Vincent Leroy, Jean-Pierre Zarski  Journal of Hepatology 
I. Carmona, P. Cordero, J. Ampuero, A. Rojas, M. Romero-Gómez 
The quest for liver progenitor cells: A practical point of view
Targeting gut flora to prevent progression of hepatocellular carcinoma
Mechanisms of iron hepatotoxicity
The yin and yang of evasion and immune activation in HCC
Nitin Raj, Laura D. Attardi  Current Biology 
Volume 146, Issue 5, Pages (May 2014)
Approaches for treatment of liver fibrosis in chronic hepatitis C
Volume 59, Issue 3, Pages (September 2013)
Sinusoidal communication in liver fibrosis and regeneration
Hepatic fibrosis: Concept to treatment
Veronika Lukacs-Kornek, Detlef Schuppan  Journal of Hepatology 
YAPping About Glutaminolysis in Hepatic Fibrosis
Cannabinoid signaling and liver therapeutics
Liver fibrosis – from bench to bedside
Antifibrotic therapy in chronic liver disease
Senescence in chronic liver disease: Is the future in aging?
Volume 50, Issue 4, Pages (April 2009)
Cédric Coulouarn, Bruno Clément  Journal of Hepatology 
Paul C. Adams, James C. Barton  Journal of Hepatology 
NASH animal models: Are we there yet?
Volume 61, Issue 1, Pages S79-S90 (November 2014)
Immigration and viral hepatitis
Role of desmoplasia in cholangiocarcinoma and hepatocellular carcinoma
Volume 63, Issue 1, Pages (July 2015)
Macrophage heterogeneity in liver injury and fibrosis
The dynamic biliary epithelia: Molecules, pathways, and disease
Autophagy in liver diseases: Time for translation?
Silvia Affò, Ramón Bataller  Journal of Hepatology 
Volume 132, Issue 5, Pages (May 2007)
Tatiana Kisseleva, David A. Brenner  Journal of Hepatology 
Statins: Old drugs as new therapy for liver diseases?
Pathogenesis of cholestatic hepatitis C
Corrigendum to “Antibody-targeted myofibroblast apoptosis reduces fibrosis during sustained liver injury” [J Hepatol 49 (2008) 88–98]  Angela Douglass,
Volume 61, Issue 2, Pages (August 2014)
Platelets arrive at the scene of fibrosis……studies
Niya Aleksieva, Stuart J. Forbes  Journal of Hepatology 
Presentation transcript:

Reversion of hepatic stellate cell to a quiescent phenotype: From myth to reality?  Ariane Mallat, Sophie Lotersztajn  Journal of Hepatology  Volume 59, Issue 2, Pages 383-386 (August 2013) DOI: 10.1016/j.jhep.2013.03.031 Copyright © 2013 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Fate of hepatic stellate cells during liver fibrosis progression and resolution. Upon liver injury, HSCs undergo transdifferentiation from a quiescent to a myofibroblastic phenotype. The process is orchestrated by interactions with neighboring parenchymal and non-parenchymal cells (immune cells, capillarized liver sinusoidal endothelial cells), and by cell matrix components, interactions mediated through integrins, and matrix stiffness. Activated HSCs are characterized by enhanced capacity to proliferate and produce proinflammatory and profibrogenic mediators and are responsible for secreting extracellular matrix that characterizes liver fibrosis. Clearance of activated HSC is a key step in fibrosis regression, and may result from apoptosis, promoted by NK cells, dendritic cells, and proresolution macrophages, or from reversion to a quiescent phenotype. The studies of Troeger and Kisseleva demonstrate significant reversion/inactivation of myofibroblastic HSC in animals undergoing fibrosis recovery. However, deactivated HSC do not fully revert to a quiescent state, but retain a preactivated intermediate state and show enhanced susceptibility to subsequent insult. Journal of Hepatology 2013 59, 383-386DOI: (10.1016/j.jhep.2013.03.031) Copyright © 2013 European Association for the Study of the Liver Terms and Conditions